126 related articles for article (PubMed ID: 6461409)
1. Pharmacology and toxicity of a potent "nonclassical" 2,4-diamino quinazoline folate antagonist, trimetrexate, in normal dogs.
Weir EC; Cashmore AR; Dreyer RN; Graham ML; Hsiao N; Moroson BA; Sawicki WL; Bertino JR
Cancer Res; 1982 May; 42(5):1696-702. PubMed ID: 6461409
[TBL] [Abstract][Full Text] [Related]
2. Phase I studies with trimetrexate: clinical pharmacology, analytical methodology, and pharmacokinetics.
Lin JT; Cashmore AR; Baker M; Dreyer RN; Ernstoff M; Marsh JC; Bertino JR; Whitfield LR; Delap R; Grillo-Lopez A
Cancer Res; 1987 Jan; 47(2):609-16. PubMed ID: 2947679
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of trimetrexate (NSC 352122) in monkeys.
Balis FM; Lester CM; Poplack DG
Cancer Res; 1986 Jan; 46(1):169-74. PubMed ID: 2933145
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology of a new triazine antifolate in mice, rats, dogs, and monkeys.
Cashmore AR; Skeel RT; Makulu DR; Gralla EJ; Bertino JR
Cancer Res; 1975 Jan; 35(1):17-22. PubMed ID: 803254
[TBL] [Abstract][Full Text] [Related]
5. Metabolic disposition of trimetrexate, a nonclassical dihydrofolate reductase inhibitor, in rat and dog.
Wong BK; Woolf TF; Chang T; Whitfield LR
Drug Metab Dispos; 1990; 18(6):980-6. PubMed ID: 1981548
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of trimetrexate administered by five-day continuous infusion to patients with advanced cancer.
Reece PA; Morris RG; Bishop JF; Olver IN; Raghavan D
Cancer Res; 1987 Jun; 47(11):2996-9. PubMed ID: 2952262
[TBL] [Abstract][Full Text] [Related]
7. Pediatric phase I trial and pharmacokinetic study of trimetrexate.
Balis FM; Patel R; Luks E; Doherty KM; Holcenberg JS; Tan C; Reaman GH; Belasco J; Ettinger LJ; Zimm S
Cancer Res; 1987 Sep; 47(18):4973-6. PubMed ID: 2957048
[TBL] [Abstract][Full Text] [Related]
8. Absorption, distribution and excretion of [carbonyl-14C]mosapride citrate after a single oral administration in rats, dogs and monkeys.
Matsumoto S; Tagawa M; Amejima H; Nakao M; Kagemoto A; Fujii T; Miyazaki H; Sekine Y
Arzneimittelforschung; 1993 Oct; 43(10):1084-94. PubMed ID: 8267675
[TBL] [Abstract][Full Text] [Related]
9. Preclinical pharmacology of the novel antitumor agent adaphostin, a tyrphostin analog that inhibits bcr/abl.
Li M; Wang H; Hill DL; Stinson S; Veley K; Grossi I; Peggins J; Covey JM; Zhang R
Cancer Chemother Pharmacol; 2006 May; 57(5):607-14. PubMed ID: 16331493
[TBL] [Abstract][Full Text] [Related]
10. Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations.
Piper JR; Johnson CA; Krauth CA; Carter RL; Hosmer CA; Queener SF; Borotz SE; Pfefferkorn ER
J Med Chem; 1996 Mar; 39(6):1271-80. PubMed ID: 8632434
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of prulifloxacin. 1st communication: absorption, distribution and excretion in rats, dogs and monkeys after a single administration.
Okuyama Y; Momota K; Morino A
Arzneimittelforschung; 1997 Mar; 47(3):276-84. PubMed ID: 9105546
[TBL] [Abstract][Full Text] [Related]
12. Toxicity and pharmacokinetics of a new antifolate, 2,4-diamino-5-adamantyl-6-methylpyrimidine, in dogs.
Zakrzewski SF; Pavelic Z; Greco WR; Bullard G; Creaven PJ; Mihich E
Cancer Res; 1982 Jun; 42(6):2177-83. PubMed ID: 7074598
[TBL] [Abstract][Full Text] [Related]
13. Nonclassical 2,4-diamino-8-deazafolate analogues as inhibitors of dihydrofolate reductases from rat liver, Pneumocystis carinii, and Toxoplasma gondii.
Gangjee A; Zhu Y; Queener SF; Francom P; Broom AD
J Med Chem; 1996 Apr; 39(9):1836-45. PubMed ID: 8627607
[TBL] [Abstract][Full Text] [Related]
14. Establishment of methotrexate-resistant human acute lymphoblastic leukemia cells in culture and effects of folate antagonists.
Ohnoshi T; Ohnuma T; Takahashi I; Scanlon K; Kamen BA; Holland JF
Cancer Res; 1982 May; 42(5):1655-60. PubMed ID: 6978176
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of metabolism of the 'nonclassical' antifolate, trimetrexate (2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline) by drugs containing an imidazole moiety.
Heusner JJ; Franklin MR
Pharmacology; 1985; 30(5):266-72. PubMed ID: 3159026
[TBL] [Abstract][Full Text] [Related]
16. Absorption, distribution, metabolism and excretion of [14C]ebastine after a single administration in rats.
Fujii T; Matsumoto S; Amejima H; Hatoyama T; Nakao M; Kagemoto A; Tanaka K; Miyazaki H
Arzneimittelforschung; 1994 Apr; 44(4):527-38. PubMed ID: 7912071
[TBL] [Abstract][Full Text] [Related]
17. High performance liquid chromatographic analysis and preclinical pharmacokinetics of the heteroarotinoid antitumor agent, SHetA2.
Zhang Y; Hua Y; Benbrook DM; Covey JM; Dai G; Liu Z; Chan KK
Cancer Chemother Pharmacol; 2006 Nov; 58(5):561-9. PubMed ID: 16534614
[TBL] [Abstract][Full Text] [Related]
18. Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance.
Glaze ER; Lambert AL; Smith AC; Page JG; Johnson WD; McCormick DL; Brown AP; Levine BS; Covey JM; Egorin MJ; Eiseman JL; Holleran JL; Sausville EA; Tomaszewski JE
Cancer Chemother Pharmacol; 2005 Dec; 56(6):637-47. PubMed ID: 15986212
[TBL] [Abstract][Full Text] [Related]
19. Comparison of pharmacokinetics of M1, M2, M3, and M4 after intravenous administration of DA-125 or ME2303 to mice and rats. New adriamycin analogues containing fluorine.
Yoon EJ; Lee WI; Shim HJ; Lee SD; Kim WB; Yang J; Lee MG
Biopharm Drug Dispos; 1996 Jul; 17(5):373-420. PubMed ID: 8830976
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs.
Thompson KL; Vincent SH; Miller RR; Colletti AE; Alvaro RF; Wallace MA; Feeney WP; Chiu SH
Drug Metab Dispos; 1997 Oct; 25(10):1113-8. PubMed ID: 9321512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]